RegisterPROS - a Registry for Prostate Cancers

Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT). Survival is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. One challenge is to develop accurate non-invasive tests that can detect prostate cancer disease activity. A second challenge is to evaluate the effectiveness of such biomarkers during the natural history of this disease (e.g., active surveillance). A third aim is to identify whether molecular markers can predict response to different therapies (either pre-treatment, or early on during the first few cycles of a therapy). RegisterPROS registry aims at collecting data and blood samples from patients being evaluated for PCa disease. Data will be entered prospectively and anonymized after informed consent. All physicians who treat PCas are invited to participate to the registry. Data will be evaluated within regular time frames, focusing on diagnostic accuracy for biomarkers in the different types of tumors, treatment modalities and patient outcomes (e.g. disease recurrence and survival), thereby contributing to an understanding of the role of biomarkers in tumor management.

NCT Number	NCT06872619
Lead Sponsor	Wren Laboratories LLC Collaborators: Münster University Hospital, Germany
Conditions	Prostate Cancer (Adenocarcinoma), Prostate Biopsy, Prostatectomy, Radioligand, Chemotherapy, Androgen Deprivation Therapy, PSA
Enrollment	1,000 participants
Start Date	2020-01-15
Primary Completion	2025-12-15 (estimated)
Study Completion	2030-12-15 (estimated)
Updated on ClinicalTrials.gov	2025-03-12